Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medicago Inc MDCGF

GREY:MDCGF - Post Discussion

Medicago Inc > Did I say money over expediancy
View:
Post by luckyluuke on Apr 27, 2013 1:38am

Did I say money over expediancy

"Adimmune Corporation said if the firm receives a vaccine strain at the earliest possible juncture then a vaccine could be available by November at the earliest". Also read an article where Novartis can do 3,000,000 doses a month, eventually. Really do we all need to wait that long when the technology is right here, right now. How many people are they willing to sacrifice, for the profit of big Pharma. Or will one of them bite the bullet and buy out MDG at rock bottom prices? Make it go up people so they cannot do that, unlesss they are already holding it down. I reread this post and wonder "am I getting paranoid, or am I paranoid enough?"

https://yourhealth.asiaone.com/content/expert-warns-h7n9-more-powerful-sars/page/0/1

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities